• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Relmada Therapeutics Inc (NQ: RLMD )

    3.490 +0.010 (+0.29%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Relmada Therapeutics Inc

    < Previous 1 2 3 4 Next >
    RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024
    RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    7 Penny Biotech Stocks to Triple Your Investment
    Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
    Via InvestorPlace
    RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024
    RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
    RLMD stock results show that Relmada Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Recap: Relmada Therapeutics Q4 Earnings
    Via Benzinga
    Earnings Outlook For Relmada Therapeutics
    Via Benzinga
    Earnings Outlook For Relmada Therapeutics
    Via Benzinga
    Earnings Scheduled For March 19, 2024
    Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. 
    Via Benzinga
    Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
    The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
    Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3... 
    Via Benzinga
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
    Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
    Via Benzinga
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick
    For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly. 
    Via InvestorPlace
    Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.